KLK3 and metastatic prostate carcinoma: While PSA screening has been shown to reduce metastatic prostate cancer and disease-related death, there are downsides to screening including false-positive tests leading to unnecessary biopsies, overdetection of insignificant cancers, and treatment-related complications [27, 28].